JP2012508017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508017A5 JP2012508017A5 JP2011535651A JP2011535651A JP2012508017A5 JP 2012508017 A5 JP2012508017 A5 JP 2012508017A5 JP 2011535651 A JP2011535651 A JP 2011535651A JP 2011535651 A JP2011535651 A JP 2011535651A JP 2012508017 A5 JP2012508017 A5 JP 2012508017A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 229
- 210000004602 germ cell Anatomy 0.000 claims 66
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 41
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 41
- 238000006467 substitution reaction Methods 0.000 claims 37
- 150000001413 amino acids Chemical class 0.000 claims 23
- 125000000539 amino acid group Chemical group 0.000 claims 20
- 102000040430 polynucleotide Human genes 0.000 claims 16
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 239000002157 polynucleotide Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 14
- 101000839682 Homo sapiens Immunoglobulin heavy variable 4-34 Proteins 0.000 claims 13
- 102100028306 Immunoglobulin heavy variable 4-34 Human genes 0.000 claims 13
- 101001091242 Homo sapiens Immunoglobulin kappa joining 1 Proteins 0.000 claims 11
- 102100034892 Immunoglobulin kappa joining 1 Human genes 0.000 claims 11
- 101000839684 Homo sapiens Immunoglobulin heavy variable 4-31 Proteins 0.000 claims 10
- 102100028310 Immunoglobulin heavy variable 4-31 Human genes 0.000 claims 10
- 102220353972 c.292T>G Human genes 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 9
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 9
- 101000998947 Homo sapiens Immunoglobulin heavy variable 1-46 Proteins 0.000 claims 9
- 102100036888 Immunoglobulin heavy variable 1-46 Human genes 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 102220587343 Cellular tumor antigen p53_S99P_mutation Human genes 0.000 claims 8
- 101001138133 Homo sapiens Immunoglobulin kappa variable 1-5 Proteins 0.000 claims 7
- 102100020769 Immunoglobulin kappa variable 1-5 Human genes 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 102220228928 rs1064793060 Human genes 0.000 claims 7
- 102220040126 rs371657037 Human genes 0.000 claims 7
- 101000989062 Homo sapiens Immunoglobulin heavy variable 5-51 Proteins 0.000 claims 6
- 102100029414 Immunoglobulin heavy variable 5-51 Human genes 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 6
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102200115585 rs539699299 Human genes 0.000 claims 6
- 102220046035 rs587782586 Human genes 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 102220495789 Alkaline ceramidase 1_S28A_mutation Human genes 0.000 claims 5
- 102220590441 Epoxide hydrolase 3_S30D_mutation Human genes 0.000 claims 5
- 102220554706 Holliday junction recognition protein_S30T_mutation Human genes 0.000 claims 5
- 101000956885 Homo sapiens Immunoglobulin lambda variable 2-14 Proteins 0.000 claims 5
- 102100038429 Immunoglobulin lambda variable 2-14 Human genes 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 102000044457 human DLL4 Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 102200006408 rs746834149 Human genes 0.000 claims 5
- 102220123567 rs886043442 Human genes 0.000 claims 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 4
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 4
- 101000978126 Homo sapiens Immunoglobulin lambda variable 8-61 Proteins 0.000 claims 4
- 102100023752 Immunoglobulin lambda variable 8-61 Human genes 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 102220265335 rs139105272 Human genes 0.000 claims 4
- 102220259666 rs550137245 Human genes 0.000 claims 4
- 102220562905 Bromodomain-containing protein 1_I51K_mutation Human genes 0.000 claims 3
- 102220597389 G0/G1 switch protein 2_R54A_mutation Human genes 0.000 claims 3
- 101001079285 Homo sapiens Immunoglobulin heavy joining 1 Proteins 0.000 claims 3
- 101000998952 Homo sapiens Immunoglobulin heavy variable 1-3 Proteins 0.000 claims 3
- 101000989060 Homo sapiens Immunoglobulin heavy variable 6-1 Proteins 0.000 claims 3
- 101001138128 Homo sapiens Immunoglobulin kappa variable 1-12 Proteins 0.000 claims 3
- 101001047617 Homo sapiens Immunoglobulin kappa variable 3-11 Proteins 0.000 claims 3
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 claims 3
- 101001134437 Homo sapiens Immunoglobulin lambda joining 1 Proteins 0.000 claims 3
- 102100028078 Immunoglobulin heavy joining 1 Human genes 0.000 claims 3
- 102100036886 Immunoglobulin heavy variable 1-3 Human genes 0.000 claims 3
- 102100029416 Immunoglobulin heavy variable 6-1 Human genes 0.000 claims 3
- 102100020773 Immunoglobulin kappa variable 1-12 Human genes 0.000 claims 3
- 102100022955 Immunoglobulin kappa variable 3-11 Human genes 0.000 claims 3
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 claims 3
- 102100034172 Immunoglobulin lambda joining 1 Human genes 0.000 claims 3
- 102220580970 Induced myeloid leukemia cell differentiation protein Mcl-1_I50T_mutation Human genes 0.000 claims 3
- 102220601218 Microtubule-associated protein tau_T30A_mutation Human genes 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102000005650 Notch Receptors Human genes 0.000 claims 3
- 108010070047 Notch Receptors Proteins 0.000 claims 3
- 102220613568 Potassium voltage-gated channel subfamily H member 2_F29A_mutation Human genes 0.000 claims 3
- 102220509115 Sphingosine 1-phosphate receptor 1_Y97V_mutation Human genes 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims 3
- 102200075235 rs118204106 Human genes 0.000 claims 3
- 102220043120 rs144094344 Human genes 0.000 claims 3
- 102220012182 rs373164247 Human genes 0.000 claims 3
- 102200094314 rs74315399 Human genes 0.000 claims 3
- 102100036312 5-hydroxytryptamine receptor 1E Human genes 0.000 claims 2
- 102220554162 APC membrane recruitment protein 1_I34A_mutation Human genes 0.000 claims 2
- 102220625606 Ankyrin repeat domain-containing protein 2_S94G_mutation Human genes 0.000 claims 2
- 102220547840 Apoptosis-associated speck-like protein containing a CARD_L25Q_mutation Human genes 0.000 claims 2
- 102220475086 Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6_L90A_mutation Human genes 0.000 claims 2
- 102220523639 C-C motif chemokine 2_S50Q_mutation Human genes 0.000 claims 2
- 102220587363 Cellular tumor antigen p53_S94L_mutation Human genes 0.000 claims 2
- 102220566212 Cyclic AMP-dependent transcription factor ATF-7_T51A_mutation Human genes 0.000 claims 2
- 102220566211 Cyclic AMP-dependent transcription factor ATF-7_T51D_mutation Human genes 0.000 claims 2
- 102220632031 Decorin_D54A_mutation Human genes 0.000 claims 2
- 102220632043 Decorin_D56A_mutation Human genes 0.000 claims 2
- 102220526112 Dihydrofolate reductase_M92F_mutation Human genes 0.000 claims 2
- 102220526111 Dihydrofolate reductase_M92L_mutation Human genes 0.000 claims 2
- 102220519145 E3 ubiquitin/ISG15 ligase TRIM25_V89G_mutation Human genes 0.000 claims 2
- 102220475128 Ectodysplasin-A_W33A_mutation Human genes 0.000 claims 2
- 102220559985 Epsilon-sarcoglycan_M92T_mutation Human genes 0.000 claims 2
- 102220511662 Heme oxygenase 1_S58A_mutation Human genes 0.000 claims 2
- 102220588493 Hemoglobin subunit beta_T51K_mutation Human genes 0.000 claims 2
- 102220483804 High mobility group protein B1_Y97H_mutation Human genes 0.000 claims 2
- 102220471962 Histone deacetylase 7_S55W_mutation Human genes 0.000 claims 2
- 101000998951 Homo sapiens Immunoglobulin heavy variable 1-8 Proteins 0.000 claims 2
- 101001047618 Homo sapiens Immunoglobulin kappa variable 3-15 Proteins 0.000 claims 2
- 101000978120 Homo sapiens Probable non-functional immunoglobulin lambda variable 11-55 Proteins 0.000 claims 2
- 101001005499 Homo sapiens Probable non-functional immunoglobulin lambda variable 5-48 Proteins 0.000 claims 2
- 101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 102220511640 Immunoglobulin heavy joining 1_S30L_mutation Human genes 0.000 claims 2
- 102100036885 Immunoglobulin heavy variable 1-8 Human genes 0.000 claims 2
- 102100022965 Immunoglobulin kappa variable 3-15 Human genes 0.000 claims 2
- 102220478979 Interleukin-4 receptor subunit alpha_Y99A_mutation Human genes 0.000 claims 2
- 102220497573 Leukotriene B4 receptor 1_N52A_mutation Human genes 0.000 claims 2
- 102220486635 Mannose-1-phosphate guanyltransferase beta_S56A_mutation Human genes 0.000 claims 2
- 102220503895 Meiotic recombination protein REC8 homolog_S92V_mutation Human genes 0.000 claims 2
- 102220637445 Mitochondrial genome maintenance exonuclease 1_M92A_mutation Human genes 0.000 claims 2
- 102220537350 Neural retina-specific leucine zipper protein_S50L_mutation Human genes 0.000 claims 2
- 102220502536 Platelet-activating factor acetylhydrolase IB subunit alpha2_G55E_mutation Human genes 0.000 claims 2
- 102100023451 Probable non-functional immunoglobulin lambda variable 11-55 Human genes 0.000 claims 2
- 102100025167 Probable non-functional immunoglobulin lambda variable 5-48 Human genes 0.000 claims 2
- 102220569743 Programmed cell death protein 6_Y91A_mutation Human genes 0.000 claims 2
- 102220465274 Purine nucleoside phosphorylase LACC1_Y52A_mutation Human genes 0.000 claims 2
- 102220612295 Putative coiled-coil domain-containing protein 144 N-terminal-like_S55D_mutation Human genes 0.000 claims 2
- 102220615003 RELT-like protein 2_G100L_mutation Human genes 0.000 claims 2
- 102220573220 Ras-related protein Ral-A_S50W_mutation Human genes 0.000 claims 2
- -1 S100H Proteins 0.000 claims 2
- 102220509670 SAM and SH3 domain-containing protein 1_Y31A_mutation Human genes 0.000 claims 2
- 102220471545 Single-stranded DNA cytosine deaminase_S26A_mutation Human genes 0.000 claims 2
- 102220471558 Single-stranded DNA cytosine deaminase_S94A_mutation Human genes 0.000 claims 2
- 102220578494 Suppressor of fused homolog_R95A_mutation Human genes 0.000 claims 2
- 102220522291 THAP domain-containing protein 1_S31A_mutation Human genes 0.000 claims 2
- 102220536914 Transcription factor JunD_P33A_mutation Human genes 0.000 claims 2
- 102220469971 Tryptase delta_Y32A_mutation Human genes 0.000 claims 2
- 102220534415 Tyrosine-protein phosphatase non-receptor type 1_S50D_mutation Human genes 0.000 claims 2
- 102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 claims 2
- 102220474577 Ubiquitin-conjugating enzyme E2 D1_S94E_mutation Human genes 0.000 claims 2
- 102220546632 Voltage-dependent L-type calcium channel subunit beta-2_S55N_mutation Human genes 0.000 claims 2
- 102220532163 WW domain-binding protein 11_I51S_mutation Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 102220361905 c.148A>C Human genes 0.000 claims 2
- 102220352372 c.148T>G Human genes 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 102200006655 rs104894230 Human genes 0.000 claims 2
- 102200041211 rs104894459 Human genes 0.000 claims 2
- 102220209728 rs1057523598 Human genes 0.000 claims 2
- 102220216591 rs1060503509 Human genes 0.000 claims 2
- 102220230165 rs1064793071 Human genes 0.000 claims 2
- 102220003317 rs137852699 Human genes 0.000 claims 2
- 102220187877 rs143008696 Human genes 0.000 claims 2
- 102220328414 rs1453134737 Human genes 0.000 claims 2
- 102220280629 rs1555085496 Human genes 0.000 claims 2
- 102220276093 rs1555932427 Human genes 0.000 claims 2
- 102200079914 rs193302884 Human genes 0.000 claims 2
- 102200097284 rs199472834 Human genes 0.000 claims 2
- 102200097263 rs199472844 Human genes 0.000 claims 2
- 102200133096 rs199473644 Human genes 0.000 claims 2
- 102220011589 rs200960071 Human genes 0.000 claims 2
- 102220011222 rs281865133 Human genes 0.000 claims 2
- 102220006845 rs281874706 Human genes 0.000 claims 2
- 102200043447 rs281875243 Human genes 0.000 claims 2
- 102200043446 rs281875252 Human genes 0.000 claims 2
- 102200110749 rs28941476 Human genes 0.000 claims 2
- 102200082820 rs33960931 Human genes 0.000 claims 2
- 102220005308 rs33960931 Human genes 0.000 claims 2
- 102220015169 rs397517383 Human genes 0.000 claims 2
- 102220044474 rs587781329 Human genes 0.000 claims 2
- 102220045199 rs587781908 Human genes 0.000 claims 2
- 102220094065 rs587782586 Human genes 0.000 claims 2
- 102200030476 rs615942 Human genes 0.000 claims 2
- 102220169097 rs61730848 Human genes 0.000 claims 2
- 102220289621 rs63750336 Human genes 0.000 claims 2
- 102200101937 rs72554349 Human genes 0.000 claims 2
- 102220337697 rs72555390 Human genes 0.000 claims 2
- 102200006406 rs746834149 Human genes 0.000 claims 2
- 102220224491 rs765799649 Human genes 0.000 claims 2
- 102220234886 rs778952116 Human genes 0.000 claims 2
- 102220068510 rs794727508 Human genes 0.000 claims 2
- 102220094066 rs876659747 Human genes 0.000 claims 2
- 102200153318 rs913934445 Human genes 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 102220496020 5-hydroxytryptamine receptor 3B_N52S_mutation Human genes 0.000 claims 1
- 102220497137 5-hydroxytryptamine receptor 3B_S30G_mutation Human genes 0.000 claims 1
- 102220497105 5-hydroxytryptamine receptor 3B_T56A_mutation Human genes 0.000 claims 1
- 102220485321 ATP-dependent DNA/RNA helicase DHX36_G55L_mutation Human genes 0.000 claims 1
- 102220511774 Adenylosuccinate lyase_S31N_mutation Human genes 0.000 claims 1
- 108700028369 Alleles Proteins 0.000 claims 1
- 102220479279 Anoctamin-3_N52T_mutation Human genes 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 102220617612 B-cell acute lymphoblastic leukemia-expressed protein_N93H_mutation Human genes 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102220518361 Casein kinase I isoform gamma-2_Y33A_mutation Human genes 0.000 claims 1
- 102220569940 Cytochrome P450 1B1_S28W_mutation Human genes 0.000 claims 1
- 102220632024 Decorin_N53A_mutation Human genes 0.000 claims 1
- 102220510722 Dual specificity tyrosine-phosphorylation-regulated kinase 2_S98G_mutation Human genes 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 102220529131 Eukaryotic translation initiation factor 2 subunit 1_S53P_mutation Human genes 0.000 claims 1
- 108010008177 Fd immunoglobulins Proteins 0.000 claims 1
- 102220607093 Gap junction beta-1 protein_S52P_mutation Human genes 0.000 claims 1
- 102220619583 Glycine receptor subunit alpha-1_G55V_mutation Human genes 0.000 claims 1
- 102220543692 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas_N53G_mutation Human genes 0.000 claims 1
- 102220511665 Heme oxygenase 1_S76A_mutation Human genes 0.000 claims 1
- 102220537095 Hemoglobin subunit epsilon_N53H_mutation Human genes 0.000 claims 1
- 102220491788 High mobility group protein B1_S53E_mutation Human genes 0.000 claims 1
- 101001008293 Homo sapiens Immunoglobulin kappa variable 2D-40 Proteins 0.000 claims 1
- 102100027409 Immunoglobulin kappa variable 2D-40 Human genes 0.000 claims 1
- 102220631528 Krueppel-like factor 13_G55W_mutation Human genes 0.000 claims 1
- 102220497574 Leukotriene B4 receptor 1_N52Q_mutation Human genes 0.000 claims 1
- 102220642036 Lipoma-preferred partner_S76N_mutation Human genes 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102220482828 Mitochondrial coenzyme A diphosphatase NUDT8_E96A_mutation Human genes 0.000 claims 1
- 102220612416 Mitogen-activated protein kinase kinase kinase 1_S92N_mutation Human genes 0.000 claims 1
- 102220631334 NCK-interacting protein with SH3 domain_S92G_mutation Human genes 0.000 claims 1
- 102220537824 Nebulette_S99A_mutation Human genes 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 102220572954 Netrin receptor UNC5C_S28F_mutation Human genes 0.000 claims 1
- 102220592550 Neuroserpin_S52R_mutation Human genes 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102220510219 Poly(A)-specific ribonuclease PNLDC1_S31G_mutation Human genes 0.000 claims 1
- 102220559090 Potassium voltage-gated channel subfamily E member 1_S28T_mutation Human genes 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102220467908 Protein Dok-7_S30W_mutation Human genes 0.000 claims 1
- 102220519841 Putative neutrophil cytosol factor 1B_S30P_mutation Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 102220596972 Ski oncogene_S31L_mutation Human genes 0.000 claims 1
- 102220606007 Sorting nexin-10_Y32S_mutation Human genes 0.000 claims 1
- 101100226845 Strongylocentrotus purpuratus EGF2 gene Proteins 0.000 claims 1
- 102220536512 THAP domain-containing protein 1_S52A_mutation Human genes 0.000 claims 1
- 102220521977 THAP domain-containing protein 1_T28A_mutation Human genes 0.000 claims 1
- 102220504159 Testis-specific XK-related protein, Y-linked 2_N93Q_mutation Human genes 0.000 claims 1
- 102220524532 Tumor necrosis factor receptor superfamily member 19_S31T_mutation Human genes 0.000 claims 1
- 206010046798 Uterine leiomyoma Diseases 0.000 claims 1
- 102220594970 Vasopressin-neurophysin 2-copeptin_T51N_mutation Human genes 0.000 claims 1
- 102220514520 Vitronectin_T76E_mutation Human genes 0.000 claims 1
- 102220559219 Voltage-dependent L-type calcium channel subunit alpha-1C_S30R_mutation Human genes 0.000 claims 1
- 102220469732 Voltage-dependent L-type calcium channel subunit beta-2_S53A_mutation Human genes 0.000 claims 1
- 102220532167 WW domain-binding protein 11_D50S_mutation Human genes 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 102200016928 c.100G>A Human genes 0.000 claims 1
- 102220437982 c.160G>T Human genes 0.000 claims 1
- 102220353096 c.163G>C Human genes 0.000 claims 1
- 102220290142 c.186C>A Human genes 0.000 claims 1
- 102220349282 c.275C>G Human genes 0.000 claims 1
- 102220358598 c.296C>G Human genes 0.000 claims 1
- 102200107976 c.296C>T Human genes 0.000 claims 1
- 102220346421 c.92C>A Human genes 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 102200103823 rs104886043 Human genes 0.000 claims 1
- 102200046706 rs104893869 Human genes 0.000 claims 1
- 102200046707 rs104893869 Human genes 0.000 claims 1
- 102200076230 rs104894127 Human genes 0.000 claims 1
- 102200142367 rs104894554 Human genes 0.000 claims 1
- 102220196624 rs1057518977 Human genes 0.000 claims 1
- 102220218621 rs1060501106 Human genes 0.000 claims 1
- 102220233028 rs1085307691 Human genes 0.000 claims 1
- 102220028823 rs115928999 Human genes 0.000 claims 1
- 102200148733 rs116840794 Human genes 0.000 claims 1
- 102200118914 rs120074145 Human genes 0.000 claims 1
- 102200058924 rs121909542 Human genes 0.000 claims 1
- 102200115358 rs121918322 Human genes 0.000 claims 1
- 102220036452 rs137882485 Human genes 0.000 claims 1
- 102220191772 rs149875299 Human genes 0.000 claims 1
- 102220318984 rs150326789 Human genes 0.000 claims 1
- 102200061168 rs150338273 Human genes 0.000 claims 1
- 102220242992 rs1553178041 Human genes 0.000 claims 1
- 102220317885 rs1554069716 Human genes 0.000 claims 1
- 102220320206 rs1554431444 Human genes 0.000 claims 1
- 102220287941 rs1555932714 Human genes 0.000 claims 1
- 102200048328 rs1801270 Human genes 0.000 claims 1
- 102200133063 rs199473350 Human genes 0.000 claims 1
- 102220008235 rs199476326 Human genes 0.000 claims 1
- 102200082871 rs35802118 Human genes 0.000 claims 1
- 102220084157 rs370502517 Human genes 0.000 claims 1
- 102220240604 rs373669452 Human genes 0.000 claims 1
- 102200050844 rs386833793 Human genes 0.000 claims 1
- 102220016203 rs397507622 Human genes 0.000 claims 1
- 102220020162 rs397508045 Human genes 0.000 claims 1
- 102220139130 rs570799464 Human genes 0.000 claims 1
- 102220041238 rs587778670 Human genes 0.000 claims 1
- 102200114146 rs61748123 Human genes 0.000 claims 1
- 102200001738 rs72552724 Human genes 0.000 claims 1
- 102200123491 rs72555390 Human genes 0.000 claims 1
- 102220058298 rs730881402 Human genes 0.000 claims 1
- 102220218616 rs746322193 Human genes 0.000 claims 1
- 102220082204 rs753215899 Human genes 0.000 claims 1
- 102220315596 rs762200707 Human genes 0.000 claims 1
- 102220121884 rs768260007 Human genes 0.000 claims 1
- 102220092171 rs770694213 Human genes 0.000 claims 1
- 102220463950 rs7782939 Human genes 0.000 claims 1
- 102220328494 rs78028658 Human genes 0.000 claims 1
- 102220097978 rs780920036 Human genes 0.000 claims 1
- 102220328195 rs781611267 Human genes 0.000 claims 1
- 102220062178 rs786202417 Human genes 0.000 claims 1
- 102220087056 rs864622464 Human genes 0.000 claims 1
- 102220172123 rs886048669 Human genes 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19876408P | 2008-11-07 | 2008-11-07 | |
| US61/198,764 | 2008-11-07 | ||
| US21120409P | 2009-03-25 | 2009-03-25 | |
| US61/211,204 | 2009-03-25 | ||
| PCT/US2009/063303 WO2010054010A1 (en) | 2008-11-07 | 2009-11-04 | Anti-dll4 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015157842A Division JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012508017A JP2012508017A (ja) | 2012-04-05 |
| JP2012508017A5 true JP2012508017A5 (enExample) | 2013-01-24 |
Family
ID=41508157
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535651A Pending JP2012508017A (ja) | 2008-11-07 | 2009-11-04 | 抗ｄｌｌ４抗体及びその使用 |
| JP2011535649A Expired - Fee Related JP5882058B2 (ja) | 2008-11-07 | 2009-11-04 | 組合せ抗体ライブラリー及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535649A Expired - Fee Related JP5882058B2 (ja) | 2008-11-07 | 2009-11-04 | 組合せ抗体ライブラリー及びその使用 |
| JP2015157842A Pending JP2016040246A (ja) | 2008-11-07 | 2015-08-10 | 抗ｄｌｌ４抗体及びその使用 |
| JP2016018531A Pending JP2016127850A (ja) | 2008-11-07 | 2016-02-03 | 組合せ抗体ライブラリー及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9221902B2 (enExample) |
| EP (2) | EP2356146A1 (enExample) |
| JP (4) | JP2012508017A (enExample) |
| AU (4) | AU2009313551B2 (enExample) |
| CA (2) | CA2742968C (enExample) |
| DK (1) | DK2356270T3 (enExample) |
| WO (2) | WO2010054010A1 (enExample) |
Families Citing this family (202)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011053822A2 (en) * | 2009-11-01 | 2011-05-05 | The Brigham And Women's Hospital, Inc. | Notch inhibition in the treatment and prevention of obesity and metabolic syndrome |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| ME02371B (me) | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| MX2009012609A (es) | 2007-05-22 | 2009-12-07 | Amgen Inc | Composiciones y metodos para producir proteinas de fusion bioactivas. |
| CN101970493A (zh) | 2008-03-14 | 2011-02-09 | 百康有限公司 | 单克隆抗体及其方法 |
| EP2356146A1 (en) | 2008-11-07 | 2011-08-17 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| WO2010108153A2 (en) * | 2009-03-20 | 2010-09-23 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
| WO2010121370A1 (en) * | 2009-04-20 | 2010-10-28 | University Health Network | Prognostic gene expression signature for squamous cell carcinoma of the lung |
| US8685896B2 (en) | 2009-05-29 | 2014-04-01 | Morphosys Ag | Collection and methods for its use |
| TWI513465B (zh) * | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| EP3485908B1 (en) | 2009-10-16 | 2021-08-18 | Mereo BioPharma 5, Inc. | Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents |
| US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| US10016620B2 (en) * | 2010-02-04 | 2018-07-10 | Procept Biorobotics Incorporation | Tissue sampling and cancer treatment apparatus |
| WO2015200538A1 (en) * | 2014-06-24 | 2015-12-30 | Procept Biorobotics Corporation | Tissue sampling and cancer treatment methods and apparatus |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| ME02288B (me) | 2010-02-08 | 2016-02-20 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
| KR102318383B1 (ko) | 2010-07-16 | 2021-10-27 | 아디맵 엘엘씨 | 항체 라이브러리 |
| CA2806076A1 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| MX360946B (es) | 2010-09-22 | 2018-10-29 | Amgen Inc Star | Inmunoglobulinas portadoras y usos de las mismas. |
| CN103237809B (zh) | 2010-11-19 | 2016-09-07 | 莫佛塞斯公司 | 一个集合及其使用方法 |
| CA2834376A1 (en) * | 2011-04-28 | 2012-11-01 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Neutralizing antibodies to nipah and hendra virus |
| ES2716013T3 (es) * | 2011-04-28 | 2019-06-07 | Univ Leland Stanford Junior | Identificación de polinucleótidos asociados a una muestra |
| HRP20200887T1 (hr) * | 2011-05-04 | 2020-09-04 | Omeros Corporation | Smjese za inhibiciju masp-2 ovisne aktivacije komplementa |
| KR101629073B1 (ko) | 2011-06-15 | 2016-06-09 | 에프. 호프만-라 로슈 아게 | 항-인간 에리스로포이에틴 수용체 항체 및 이의 사용 방법 |
| CN103917650B (zh) | 2011-08-05 | 2017-10-24 | 瑞泽恩制药公司 | 人源化的通用轻链小鼠 |
| WO2013023251A1 (en) | 2011-08-18 | 2013-02-21 | Affinity Biosciences Pty Ltd | Soluble polypeptides |
| JP6170496B2 (ja) | 2011-09-23 | 2017-07-26 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用 |
| CN104053671A (zh) | 2011-11-01 | 2014-09-17 | 生态学有限公司 | 治疗癌症的抗体和方法 |
| WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| WO2013106485A2 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
| EP3663314A1 (en) | 2012-01-09 | 2020-06-10 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
| WO2013116296A1 (en) | 2012-01-31 | 2013-08-08 | Regeneron Pharmaceuticals, Inc. | Anti-asic1 antibodies and uses thereof |
| WO2013131074A1 (en) * | 2012-03-02 | 2013-09-06 | Diogenix, Inc. | Methods and reagents for evaluating autoimmune disease and determining antibody repertoire |
| JP6181089B2 (ja) | 2012-03-08 | 2017-08-16 | ハロザイム インコーポレイテッド | 条件依存活性抗上皮細胞増殖因子受容体抗体およびその使用方法 |
| US10519245B2 (en) | 2012-06-21 | 2019-12-31 | Sorrento Therapeutics Inc. | Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| US9777067B2 (en) | 2012-09-27 | 2017-10-03 | Massachusetts Institute Of Technology | HER2- and VEGF-A-binding proteins with enhanced stability |
| US9309318B2 (en) * | 2012-10-17 | 2016-04-12 | Amgen, Inc. | Compositions relating to anti-IL-21 receptor antibodies |
| WO2014071018A1 (en) * | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| EP2917236A2 (en) * | 2012-11-06 | 2015-09-16 | MedImmune, LLC | Combination therapies using anti-pseudomonas psl and pcrv binding molecules |
| WO2014085821A2 (en) * | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Fully human antibodies and fragments recognizing human c-met |
| ES2864326T3 (es) | 2012-12-05 | 2021-10-13 | Novartis Ag | Composiciones y métodos para anticuerpos dirigidos a EPO |
| AU2014210475B2 (en) * | 2013-01-24 | 2017-03-02 | Abtlas Co., Ltd. | Protein combination-based Fv library, and preparation method therefor |
| DK2989239T4 (da) * | 2013-04-25 | 2025-04-07 | Sutro Biopharma Inc | Selektion af Fab-fragmenter ved anvendelse af ribosomfremvisningsteknologi |
| EP2989202B1 (en) | 2013-04-25 | 2019-04-10 | Sutro Biopharma, Inc. | The use of lambda-gam protein in ribosomal display technology |
| RU2539752C2 (ru) * | 2013-05-23 | 2015-01-27 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ (Fab), СВЯЗЫВАЮЩИЕСЯ С ИНТЕРФЕРОНОМ- γ ЧЕЛОВЕКА, ФРАГМЕНТЫ ДНК, КОДИРУЮЩИЕ УКАЗАННОЕ АНТИТЕЛО И АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ, КЛЕТКА, ТРАНСФОРМИРОВАННАЯ ФРАГМЕНТОМ ДНК, И СПОСОБ ПОЛУЧЕНИЯ УКАЗАННОГО АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
| CA2918370A1 (en) | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Humanized antibodies with ultralong complementarity determining regions |
| ES2837392T3 (es) * | 2013-10-02 | 2021-06-30 | Medimmune Llc | Anticuerpos anti-influenza A neutralizantes y usos de los mismos |
| WO2015057906A1 (en) * | 2013-10-16 | 2015-04-23 | Janssen Biotech, Inc. | Cd200 receptor 1 agonists |
| GB201403775D0 (en) * | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| BR112016020822A2 (pt) * | 2014-03-14 | 2017-10-03 | Genentech Inc | Métodos e composições para secreção de polipeptídeos heterólogos |
| WO2015143414A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| RU2761118C2 (ru) | 2014-04-03 | 2021-12-06 | АйДжиЭм БАЙОСАЙЕНСИЗ, ИНК. | Модифицированная j-цепь |
| AU2015240599B2 (en) | 2014-04-04 | 2020-11-19 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
| GB201407852D0 (en) | 2014-05-02 | 2014-06-18 | Iontas Ltd | Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules |
| CN106573154B (zh) | 2014-07-15 | 2021-06-15 | 免疫医疗有限责任公司 | 中和抗乙型流感抗体及其用途 |
| MA40528A (fr) | 2014-08-29 | 2017-07-05 | Sorrento Therapeutics Inc | Anticorps thérapeutiques qui se lient à oprf et oprl |
| JP6709215B2 (ja) | 2014-10-27 | 2020-06-10 | エージェンシー フォー サイエンス，テクノロジー アンド リサーチ | 抗ｔｉｍ−３抗体 |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| TW201625692A (zh) | 2014-11-14 | 2016-07-16 | 諾華公司 | 抗體藥物結合物 |
| EP3026060A1 (en) * | 2014-11-26 | 2016-06-01 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for CD45R0 |
| WO2016090320A1 (en) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
| BR112017011914A2 (pt) | 2014-12-05 | 2018-02-27 | Memorial Sloan-Kettering Cancer Center | ?antígeno de maturação de célula b de direcionamento de anticorpos e métodos de uso? |
| WO2016114567A1 (ko) * | 2015-01-13 | 2016-07-21 | 이화여자대학교 산학협력단 | 신규 항체 라이브러리 제조방법 및 이로부터 제조된 라이브러리 |
| TW201639891A (zh) * | 2015-03-10 | 2016-11-16 | 索倫多醫療公司 | 結合ｐｓｍａ之抗體治療劑 |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| WO2016164669A2 (en) | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| JP6907124B2 (ja) | 2015-04-17 | 2021-07-21 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ | Ｃｄｈ３及びｃｄ３に対する二重特異性抗体構築物 |
| SG11201708804WA (en) | 2015-05-07 | 2017-11-29 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| WO2016187354A1 (en) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
| EP3297663B1 (en) | 2015-05-18 | 2025-11-12 | Agensys, Inc. | Antibodies that bind to axl proteins |
| BR112017025496A2 (pt) | 2015-06-01 | 2018-08-07 | Medimmune, Llc | Moléculas de ligação neutralizantes anti- influenza e usos das mesmas |
| US20180155411A1 (en) * | 2015-07-08 | 2018-06-07 | The Board Of Trustees Of The Leland Stanford Junior University | Heterotypic antibodies specific for human rotavirus |
| EP3334842B1 (en) | 2015-08-12 | 2022-03-02 | Novartis AG | Methods of treating ophthalmic disorders |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| WO2017059387A1 (en) | 2015-09-30 | 2017-04-06 | Igm Biosciences, Inc. | Binding molecules with modified j-chain |
| PT3355913T (pt) | 2015-09-30 | 2024-12-18 | Igm Biosciences Inc | Moléculas de ligação com cadeia j modificada |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| CA3003468C (en) | 2015-11-10 | 2024-06-18 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| AU2016364889B2 (en) | 2015-12-02 | 2024-01-04 | Agenus Inc. | Antibodies and methods of use thereof |
| WO2017096281A1 (en) * | 2015-12-02 | 2017-06-08 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
| AU2016364891A1 (en) * | 2015-12-03 | 2018-06-07 | Agenus Inc. | Anti-OX40 antibodies and methods of use thereof |
| CN106939047B (zh) * | 2016-01-04 | 2021-08-31 | 江苏怀瑜药业有限公司 | 一种pd-l1抗体及其制备方法 |
| CN105693821A (zh) * | 2016-01-08 | 2016-06-22 | 中国药科大学 | 与人血管内皮生长因子受体-3(vegfr-3)蛋白特异性结合的多肽，其筛选方法，鉴定和用途 |
| CA3010223A1 (en) | 2016-01-08 | 2017-07-13 | Aimm Therapeutics B.V. | Therapeutic binding compounds |
| US20190015509A1 (en) | 2016-01-13 | 2019-01-17 | Medimmune, Llc | Method of treating influenza a |
| US11505599B2 (en) | 2016-01-14 | 2022-11-22 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for Foxp3-derived peptides |
| EP3432925A4 (en) | 2016-03-22 | 2019-11-06 | Bionomics Limited | ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY |
| IL262207B1 (en) * | 2016-04-15 | 2025-09-01 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CA3172367A1 (en) * | 2016-06-14 | 2017-12-21 | Merck Sharp & Dohme Corp. | Anti-coagulation factor xi antibodies |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| MA45455A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées |
| WO2018049083A1 (en) | 2016-09-07 | 2018-03-15 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
| JP7274413B2 (ja) * | 2016-09-23 | 2023-05-16 | マレンゴ・セラピューティクス，インコーポレーテッド | ラムダ及びカッパ軽鎖を含む多重特異性抗体分子 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| WO2018075621A1 (en) * | 2016-10-19 | 2018-04-26 | Vanderbilt University | Human orthopoxvirus antibodies and methods of use therefor |
| WO2018081755A1 (en) * | 2016-10-29 | 2018-05-03 | University Of Miami | Zika virus antibodies |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| AU2017359439B2 (en) | 2016-11-08 | 2024-11-28 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| TW201832778A (zh) * | 2016-11-10 | 2018-09-16 | 美商麥迪紐有限責任公司 | 對ａｓｃｔ２具有特異性的結合分子及其用途 |
| EP3548515A1 (en) | 2016-12-01 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging |
| FI3555132T3 (fi) * | 2016-12-19 | 2024-02-08 | Medimmune Ltd | Vasta-aineita LIF:iä vastaan ja niiden käyttöjä |
| KR20240023449A (ko) | 2017-02-08 | 2024-02-21 | 드래곤플라이 쎄라퓨틱스, 인크. | 천연 킬러 세포의 활성화를 위한 다중-특이적 결합 단백질 및 암 치료에서의 그의 치료적 용도 |
| CN108456250B (zh) * | 2017-02-17 | 2025-11-28 | 恺兴生命科技(上海)有限公司 | 靶向il-13ra2的抗体及其应用 |
| AU2018222749B2 (en) | 2017-02-17 | 2024-04-18 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
| JP7685821B2 (ja) | 2017-02-20 | 2025-05-30 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質 |
| US11161905B2 (en) * | 2017-03-04 | 2021-11-02 | Xiangtan Tenghua Bioscience | Recombinant antibodies to programmed death 1 (PD-1) and uses thereof |
| JOP20180021A1 (ar) * | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
| US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US10296425B2 (en) | 2017-04-20 | 2019-05-21 | Bank Of America Corporation | Optimizing data processing across server clusters and data centers using checkpoint-based data replication |
| US11976121B2 (en) | 2017-07-20 | 2024-05-07 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CD123-binding chimeric antigen receptors |
| IL272367B2 (en) | 2017-07-31 | 2025-08-01 | Tizona Therapeutics | Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies |
| AU2018318303A1 (en) * | 2017-08-18 | 2020-04-09 | Gritstone Bio, Inc. | Antigen-binding proteins targeting shared antigens |
| CN111511370A (zh) | 2017-11-01 | 2020-08-07 | 朱诺治疗学股份有限公司 | 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体 |
| EP3703750B1 (en) | 2017-11-01 | 2024-12-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides |
| MA50564A (fr) | 2017-11-06 | 2020-09-16 | Hutchinson Fred Cancer Res | Association d'une thérapie cellulaire et d'un inhibiteur de gamma secrétase |
| JP7291700B2 (ja) | 2017-11-20 | 2023-06-15 | ナントバイオ，インコーポレイテッド | ｍＲＮＡディスプレイ抗体ライブラリー及び方法 |
| US11034951B2 (en) | 2017-11-20 | 2021-06-15 | Nantbio, Inc. | mRNA display antibody library and methods |
| SG11202005146VA (en) | 2017-12-18 | 2020-06-29 | Regeneron Pharma | Bispecific antigen binding molecules that bind leptin receptor and/or gp130, and methods of use thereof |
| CN111727203B (zh) | 2017-12-19 | 2024-04-26 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| JP7418332B2 (ja) | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング， インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN111699003B (zh) | 2017-12-19 | 2024-05-03 | 瑟罗泽恩奥普瑞汀公司 | 抗lrp5/6抗体和使用方法 |
| WO2019143884A1 (en) * | 2018-01-19 | 2019-07-25 | Vanderbilt University | Conserved hiv antibody clonotypes and methods of use |
| KR20200118824A (ko) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법 |
| PT3749346T (pt) | 2018-02-08 | 2024-09-05 | Dragonfly Therapeutics Inc | Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d |
| CA3091424A1 (en) | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
| JOP20200215A1 (ar) | 2018-03-05 | 2020-09-03 | Janssen Pharmaceutica Nv | الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها |
| US10738125B2 (en) * | 2018-03-13 | 2020-08-11 | Tusk Therapeutics Ltd. | Anti-CD25 antibody agents |
| AU2019249273A1 (en) | 2018-04-06 | 2020-10-15 | Regeneron Pharmaceuticals, Inc. | Methods of treatment using a leptin receptor agonist antibody |
| EP3553081A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Atrial natriuretic peptide engrafted antibodies |
| EP3553082A1 (en) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Brain natriuretic peptide engrafted antibodies |
| EP3553079A1 (en) * | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | C-type natriuretic peptide engrafted antibodies |
| WO2020010235A1 (en) * | 2018-07-05 | 2020-01-09 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Car t cells that target b-cell antigens |
| JP7332691B2 (ja) | 2018-07-08 | 2023-08-23 | スペシフィカ インコーポレイティド | 抗体の開発可能性が最大化された抗体ライブラリー |
| CN110713537B (zh) * | 2018-07-13 | 2023-04-21 | 江苏怀瑜药业有限公司 | 一种sema4d抗体及其制备方法和应用 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| SG11202101298XA (en) | 2018-08-08 | 2021-03-30 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| CA3110089A1 (en) | 2018-08-28 | 2020-03-05 | Fred Hutchinson Cancer Research Center | Methods and compositions for adoptive t cell therapy incorporating induced notch signaling |
| EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| CN109553680B (zh) * | 2018-12-12 | 2021-06-01 | 广州市第八人民医院 | 一种单克隆抗体ZKns4B8及其应用 |
| JP7506607B2 (ja) * | 2018-12-28 | 2024-06-26 | 協和キリン株式会社 | ＴｆＲに結合するバイスペシフィック抗体 |
| KR102736548B1 (ko) * | 2019-01-31 | 2024-12-02 | 난트바이오 인코포레이티드 | Mrna 디스플레이 항체 라이브러리 및 방법 |
| BR112021017537A2 (pt) | 2019-03-05 | 2021-12-14 | Nkarta Inc | Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia |
| WO2020205775A1 (en) * | 2019-03-29 | 2020-10-08 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Antibodies against programmed cell death protein 1 (pd1) and uses thereof |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| WO2020247883A2 (en) * | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| PH12021553076A1 (en) | 2019-06-07 | 2023-08-14 | Scribe Therapeutics Inc | Engineered casx systems |
| US12448462B2 (en) | 2019-06-14 | 2025-10-21 | Dana-Farber Cancer Institute, Inc. | Antibodies against MUC1 |
| US20220275095A1 (en) * | 2019-07-02 | 2022-09-01 | Surrozen Operating, Inc. | Monospecific anti-frizzled antibodies and methods of use |
| KR20220034857A (ko) * | 2019-07-16 | 2022-03-18 | 사노피 | 알츠하이머병의 치료를 위한 중화 항-아밀로이드 베타 항체 |
| WO2021061829A1 (en) | 2019-09-23 | 2021-04-01 | Twist Bioscience Corporation | Variant nucleic acid libraries for crth2 |
| JP2022548783A (ja) * | 2019-09-23 | 2022-11-21 | ツイスト バイオサイエンス コーポレーション | 単一ドメイン抗体のバリアント核酸ライブラリー |
| CN116063517A (zh) * | 2019-10-24 | 2023-05-05 | 普罗米修斯生物科学公司 | Tnf样配体1a(tl1a)的人源化抗体及其用途 |
| CN115443140A (zh) * | 2020-04-02 | 2022-12-06 | 苏州恒康生命科学有限公司 | 人ror-1抗体和抗ror-1-car-t细胞 |
| WO2021222316A2 (en) | 2020-04-27 | 2021-11-04 | Twist Bioscience Corporation | Variant nucleic acid libraries for coronavirus |
| CA3177024A1 (en) | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and clec12a |
| US20230203134A1 (en) * | 2020-05-20 | 2023-06-29 | The Trustees Of Columbia University In The City Of New York | Potent neutralizing antibodies against sars-cov-2, generation and uses thereof |
| CN111748033B (zh) * | 2020-05-27 | 2021-02-02 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 一种与新型冠状病毒np蛋白结合的分离抗体、包含其的检测试剂盒 |
| CA3184752A1 (en) * | 2020-06-12 | 2021-12-16 | Nkarta, Inc. | Genetically modified natural killer cells for cd70-directed cancer immunotherapy |
| CA3183565A1 (en) * | 2020-06-30 | 2022-01-06 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| US20230348902A1 (en) * | 2020-08-10 | 2023-11-02 | Integral Molecular, Inc. | Methods and compositions for making antibody libraries and antibodies isolated from the same |
| US20230391856A1 (en) * | 2020-10-23 | 2023-12-07 | Icahn School Of Medicine At Mount Sinai | Sars-cov-2 antibodies and uses thereof |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| KR20230118134A (ko) * | 2020-12-04 | 2023-08-10 | 이퀼리엄 아이엔씨 | CD6 high 세포 선택적 표적화 및 T eff 세포의 활성감소 방법 |
| US20240228588A1 (en) * | 2021-01-11 | 2024-07-11 | Adimab, Llc | Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| WO2022192661A1 (en) * | 2021-03-12 | 2022-09-15 | Board Of Regents, The University Of Texas System | Sars-cov-2 neutralizing antibodies and uses thereof |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| IL309422A (en) | 2021-06-17 | 2024-02-01 | Atreca Inc | Antibodies against CSP |
| MX2024000675A (es) * | 2021-07-12 | 2024-02-07 | Nkarta Inc | Composiciones y metodos de inmunoterapia celular dirigida a bcma. |
| AU2022313322A1 (en) * | 2021-07-23 | 2024-02-01 | The Trustees Of Columbia University In The City Of New York | Characterization of potent and broadly neutralizing monoclonal antibodies against sars-cov-2, its variants, and related coronaviruses and methods of use |
| CA3227549A1 (en) | 2021-07-29 | 2023-02-02 | Cephalon Llc | Compositions and methods for anti-pacap antibodies |
| KR20240049342A (ko) * | 2021-08-27 | 2024-04-16 | 얀센 바이오테크 인코포레이티드 | 항-psma 항체 및 이의 용도 |
| KR20240053607A (ko) * | 2021-08-27 | 2024-04-24 | 얀센 바이오테크 인코포레이티드 | 항-psma 방사성 접합체 및 이의 용도 |
| CN118234750A (zh) * | 2021-09-02 | 2024-06-21 | 纪念斯隆-凯特琳癌症中心 | 抗cd33抗体和其用途 |
| JP2024535740A (ja) * | 2021-09-02 | 2024-10-02 | メモリアル スローン ケタリング キャンサー センター | Ｃｄ３３を標的とする抗原認識受容体及びその使用 |
| WO2023034950A2 (en) * | 2021-09-03 | 2023-03-09 | Icahn School Of Medicine At Mount Sinai | Anti-hcmv antibodies and antigen-binding fragments thereof |
| US20230265217A1 (en) * | 2021-10-27 | 2023-08-24 | Twist Bioscience Corporation | Multispecific sars-cov-2 antibodies and methods of use |
| CN116333123A (zh) * | 2021-12-22 | 2023-06-27 | 宝船生物医药科技(上海)有限公司 | 抗tnfr2抗体及其用途 |
| US20250188189A1 (en) * | 2022-03-04 | 2025-06-12 | Coagulant Therapeutics Corporation | Human antibodies against activated protein c and uses thereof |
| JP2025534161A (ja) * | 2022-10-04 | 2025-10-14 | ミンク セラピューティクス， インコーポレイテッド | 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用 |
| WO2024194686A2 (en) | 2023-03-17 | 2024-09-26 | Oxitope Pharma B.V. | Anti-phosphocholine antibodies and methods of use thereof |
| CN116514998B (zh) * | 2023-05-12 | 2023-09-15 | 再少年(北京)生物科技有限公司 | 一种嵌合抗原受体、嵌合抗原受体-自然杀伤细胞及其在制备抗肿瘤药物中的应用 |
| WO2025010375A2 (en) * | 2023-07-03 | 2025-01-09 | Uct Bioscience Co., Ltd. | Anti-grp78 antibodies and their uses |
| WO2025015320A2 (en) * | 2023-07-12 | 2025-01-16 | Phenomic Ai | Anti-cthrc1 t cell engagers and methods of using the same |
| TW202525855A (zh) * | 2023-08-31 | 2025-07-01 | 美商艾克塞里克斯公司 | Ｉｌｔ２結合劑及其用途 |
| US20250121007A1 (en) * | 2023-10-13 | 2025-04-17 | GenCART, Inc. | Compositions for the treatment of cancer |
| US20250255980A1 (en) * | 2024-02-12 | 2025-08-14 | Mbrace Therapeutics, Inc. | Antibody-Drug Conjugates Against the Glucose-regulating Protein 78 (GRP78) |
| WO2025184137A1 (en) * | 2024-02-27 | 2025-09-04 | Adimab, Llc | Influenza antibodies and methods of use thereof |
| CN117986346B (zh) * | 2024-04-07 | 2024-07-26 | 中国人民解放军军事科学院军事医学研究院 | 一种tpo模拟肽及其应用 |
| CN120399078A (zh) * | 2025-05-08 | 2025-08-01 | 上海天泽云泰生物医药有限公司 | 靶向cd117的纳米抗体及其应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
| DK0494955T3 (da) | 1989-10-05 | 1998-10-26 | Optein Inc | Cellefri syntese og isolering af hidtil ukendte gener og polypeptider |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| US20030036092A1 (en) | 1991-11-15 | 2003-02-20 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
| US5866344A (en) | 1991-11-15 | 1999-02-02 | Board Of Regents, The University Of Texas System | Antibody selection methods using cell surface expressed libraries |
| DE69233745D1 (de) | 1991-12-02 | 2008-10-23 | Cambridge Antibody Tech | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US5965408A (en) | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| US6153410A (en) | 1997-03-25 | 2000-11-28 | California Institute Of Technology | Recombination of polynucleotide sequences using random or defined primers |
| ES2275304T3 (es) | 1997-04-04 | 2007-06-01 | Millennium Pharmaceuticals, Inc. | Nuevas composiciones de delta-3 humana y usos diagnosticos y terapeuticos para las mismas. |
| US20060122373A1 (en) | 1997-04-04 | 2006-06-08 | Millennium Pharmaceuticals, Inc. | Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof |
| JP4171528B2 (ja) | 1997-05-14 | 2008-10-22 | 旭化成株式会社 | 新規な分化抑制剤 |
| JP2002523018A (ja) | 1998-07-27 | 2002-07-30 | アムジエン・インコーポレーテツド | デルタ関連ポリペプチド |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US20020102613A1 (en) | 1999-05-18 | 2002-08-01 | Hoogenboom Hendricus Renerus Jacobus Mattheus | Novel Fab fragment libraries and methods for their use |
| GB0008419D0 (en) | 2000-04-05 | 2000-05-24 | Bioinvent Int Ab | A method for invitro molecular evolution of antibody function |
| DK1292335T3 (da) | 2000-06-23 | 2007-09-17 | Bayer Schering Pharma Ag | Kombinationer og sammensætninger, som interfererer med VEGF/VEGF og angiopoietin/Tie receptor funktion og deres anvendelse (II) |
| FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20040253242A1 (en) * | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US20030022240A1 (en) | 2001-04-17 | 2003-01-30 | Peizhi Luo | Generation and affinity maturation of antibody library in silico |
| JP2005503792A (ja) | 2001-08-22 | 2005-02-10 | ガラパゴス・ジェノミックス・ナムローゼ・フェンノートシャップ | ハイ・スループット・スクリーニングにおいて同定される骨の恒常性のモジュレーター |
| WO2003035842A2 (en) | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
| AU2003248548B2 (en) * | 2002-05-20 | 2010-03-11 | Abmaxis, Inc. | Generation and selection of protein library in silico |
| JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック， インコーポレイテッド | 合成抗体ファージライブラリー |
| EP1585767A2 (en) | 2003-01-16 | 2005-10-19 | Genentech, Inc. | Synthetic antibody phage libraries |
| US20120202710A1 (en) * | 2003-09-09 | 2012-08-09 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| US8048418B2 (en) | 2004-10-29 | 2011-11-01 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists |
| AU2006210660B2 (en) | 2005-02-01 | 2011-12-01 | Morphosys Ag | Libraries and methods for isolating antibodies |
| JP2009515516A (ja) | 2005-11-14 | 2009-04-16 | バイオレン・インク | 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化 |
| JP5489465B2 (ja) | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法 |
| WO2007137616A1 (en) | 2006-05-30 | 2007-12-06 | Millegen | Highly diversified antibody libraries |
| SG175615A1 (en) | 2006-06-06 | 2011-11-28 | Genentech Inc | Anti-dll4 antibodies and methods using same |
| JP2009539870A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 血管発生の調節ための組成物および方法 |
| MY150092A (en) | 2006-08-07 | 2013-11-29 | Regeneron Pharma | Therapeutic methods for treating vascular eye disorders with dll4 antagonists |
| ME02371B (me) * | 2006-09-29 | 2016-06-20 | Oncomed Pharm Inc | Sastojci i postupci za dijagnstikovanje i tretman raka |
| US20080100597A1 (en) | 2006-10-25 | 2008-05-01 | Macrovision Corporation | Method and apparatus to improve playability in overscan areas of a TV display |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| EP2125013A4 (en) | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | DLL4 SIGNALING INHIBITOR AND ITS USES |
| GB0709333D0 (en) * | 2007-05-15 | 2007-06-20 | Smart Targeting Ltd | Binding protein |
| EP2356146A1 (en) | 2008-11-07 | 2011-08-17 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
-
2009
- 2009-11-04 EP EP09748672A patent/EP2356146A1/en not_active Withdrawn
- 2009-11-04 WO PCT/US2009/063303 patent/WO2010054010A1/en not_active Ceased
- 2009-11-04 US US13/128,219 patent/US9221902B2/en active Active
- 2009-11-04 DK DK09748671.6T patent/DK2356270T3/da active
- 2009-11-04 AU AU2009313551A patent/AU2009313551B2/en not_active Ceased
- 2009-11-04 EP EP09748671.6A patent/EP2356270B1/en active Active
- 2009-11-04 US US13/128,236 patent/US9403904B2/en not_active Expired - Fee Related
- 2009-11-04 CA CA2742968A patent/CA2742968C/en not_active Expired - Fee Related
- 2009-11-04 JP JP2011535651A patent/JP2012508017A/ja active Pending
- 2009-11-04 AU AU2009313560A patent/AU2009313560B2/en not_active Ceased
- 2009-11-04 CA CA2742969A patent/CA2742969A1/en not_active Abandoned
- 2009-11-04 JP JP2011535649A patent/JP5882058B2/ja not_active Expired - Fee Related
- 2009-11-04 WO PCT/US2009/063299 patent/WO2010054007A1/en not_active Ceased
-
2015
- 2015-08-10 JP JP2015157842A patent/JP2016040246A/ja active Pending
- 2015-12-04 US US14/959,940 patent/US10774138B2/en active Active
-
2016
- 2016-02-03 JP JP2016018531A patent/JP2016127850A/ja active Pending
- 2016-07-07 AU AU2016204719A patent/AU2016204719A1/en not_active Abandoned
-
2018
- 2018-03-06 AU AU2018201622A patent/AU2018201622A1/en not_active Abandoned
-
2020
- 2020-08-25 US US17/002,749 patent/US20200399359A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508017A5 (enExample) | ||
| JP2023129543A5 (enExample) | ||
| IL302078A (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
| RU2019120079A (ru) | Стабильные и растворимые антитела, ингибирующие vegf | |
| JP2020152735A5 (enExample) | ||
| JP2008500815A5 (enExample) | ||
| JP2020079252A5 (enExample) | ||
| TWI769537B (zh) | 標靶ｂｃｍａ的抗體、雙專一性抗體及其用途 | |
| JP2010516229A5 (enExample) | ||
| US9556275B2 (en) | Combination therapy using anti-C-met antibody and anti-ang-2 antibody | |
| JP2023070678A5 (enExample) | ||
| JP2017500028A5 (enExample) | ||
| JP2011518125A5 (enExample) | ||
| JP2010534478A5 (enExample) | ||
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| HRP20120611T1 (hr) | Anti-il-23p19 antitijela proizvedena genetiäśkim inžinjerstvom | |
| JP2020517249A5 (enExample) | ||
| JP2014530017A5 (enExample) | ||
| ME03394B (me) | Antidllз-antitelo-pbd konjugati i nihovа upotreba | |
| IL290591B2 (en) | Antibody drug preparations (ADC) that bind to 191P4D12 proteins | |
| ME02705B (me) | Inženjerisana anti-il-23 antitela | |
| RU2009115363A (ru) | Антагонисты рецепторов для лечения метастатического рака | |
| HRP20160584T1 (hr) | Novo anti-dr5 antitijelo | |
| RU2014143770A (ru) | Новое антитело против siglec-15 | |
| RU2015146664A (ru) | Антитела, способные специфически связываться с her2 |